Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $9.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)15.37K
Market Cap
$51.99M
Enterprise Value-$36.33
Total Cash (Recent Filing)$136.15M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta1.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,351,456
10 Day Avg. Volume20,483
30 Day Avg. Volume15,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)46.85
P/FCF Ratio-0.78
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.00Price Target Upside154.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityA sizable equity base relative to very low debt gives ImageneBio greater financial flexibility than a highly levered biotech. This reduces near-term solvency pressure and preserves options to fund research, although continued losses could erode that cushion over time.
Strengthened Financial LeadershipInstalling an experienced CFO from Atara Biotherapeutics and Amgen formalizes finance oversight after interim CEO supervision. Stronger financial governance can support disciplined capital allocation, reporting and planning as the company manages development spending and future funding needs.
Focused Proprietary Antibody PipelineA defined focus on proprietary antibody therapeutics in immunology and autoimmune diseases provides a coherent development strategy for a clinical-stage company. Concentrating research resources around a specialized therapeutic area can improve strategic consistency as candidates advance through clinical development.
Bears Say
No Meaningful Current Revenue BaseNear-zero trailing revenue means ImageneBio currently lacks a meaningful commercial operating base to support its research platform. The sharp historical decline increases dependence on financing or future pipeline success and leaves little internal revenue capacity to absorb ongoing development costs.
Persistent And Widening LossesLarge continuing net and operating losses show that the current business model is not yet economically self-sustaining. Until development programs generate commercial or partnering income, this level of expense intensity can pressure equity capital and constrain the company’s ability to fund multiple initiatives.
Heavy Ongoing Cash BurnSustained negative free cash flow limits self-funding capacity and indicates that substantial cash is required to maintain operations and clinical development. The worsening trailing burn increases reliance on future financing and could reduce strategic flexibility if capital becomes more difficult to obtain.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $9.10 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $51.99M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,351,456 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (154.24% Upside)
$15.00 (154.24% Upside)
Blogger Sentiment
Bearish
IMA Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ImageneBio
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
IMA Stock 12 Month Forecast
Average Price Target
$15.00
▲(154.24% Upside)
Technical Analysis
Ownership Overview
35.80% Insiders
3.57% Mutual Funds
48.76% Other Institutional Investors
8.85% Public Companies and
Individual Investors